System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Studies

Observational Recruiting

NCT05688774 on ClinicalTrials.gov

Study of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression

Official title: Study of Progression of Hospitalized Community Acquired Pneumonia - Genetic Resistance and Susceptibility for the Evolution of Severe Sepsis in Patients With More Severe Preexisting Diseases and Immunosuppression to Complement the PROGRESS CAP Cohort

  • Sponsor: Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps
  • Collaborators: Charite University, Berlin, Germany, University of Leipzig, Jena University Hospital
  • Enrollment: 300 (Estimated)
  • Study start: 2022-02-28 (Actual)
  • Primary completion: 2027-02-28 (Estimated)
  • Study completion: 2028-02-28 (Estimated)
  • Allocation: N/a
  • InterventionModel: N/a
  • Masking: None
  • PrimaryPurpose: Other

Brief Summary

Pneumonia is a common infectious disease of the lung, often requiring treatment in the hospital. Clinical scoring systems are available, identifying patients not requiring hospitalization. However, the course of disease of patients in the hospital remains hard to predict. While most patients will recover quickly, some will, despite appropriate treatment, develop a severe course leading to sepsis and systemic responses resulting in organ dysfunction. The PROGRESS consortium aims to identify clinical, genetic, and other molecular markers and combinations there of predicting a severe course of pneumonia in the hospital. Such predictors will, for instance, support decisions on earlier transfer of patients to intensive care and thus improving outcome. PROGRESS-COMORB aims to extend findings from the previous PROGRESS study to patients with more severe preexisting conditions and immunosuppression.

Conditions

  • Pneumonia
  • Sepsis
  • Shock, Septic

Primary Outcome Measures

  • Worst measure of disease severity (Between enrollment and day six)
    Disease severity is operationalized by the Sequential Organ Failure Assessment (SOFA-score).

Countries

Germany

Locations and Investigators

  • Charité - Universitätsmedizin Berlin, Medizinische Klinik m. S. Infektiologie und Pneumologie, Berlin, Germany (Recruiting)
  • Humboldt-Klinikum Vivantes, Kardiologie und kons. Intensivmedizin, Berlin, Germany (Recruiting)
  • Gemeinschaftskrankenhaus Havelhöhe, Kardio-Pneumologie, Berlin, Germany (Recruiting)
  • Städtisches Klinikum Dessau, Innere Medizin, Dessau, Germany (Recruiting)
  • Universitätsklinikum Hamburg Eppendorf, Onkologisches Zentrum, Pneumologische Studienzentrale, Hamburg, Germany (Recruiting)
  • Universitätsklinikum Leipzig, Klinik für Onkologie, Gastroenterologie, Hepatologie, Pneumologie, Leipzig, Germany (Recruiting)
  • Klinikum St. Georg gGmbH, Klinik für Infektions-/Tropenmedizin und Nephrologie, Leipzig, Germany (Recruiting)
  • Universitätsklinikum Gießen und Marburg, Klinik für Pneumologie und Anästhesie, Marburg, Germany (Recruiting)
  • Universitätsklinikum Münster, Kardiologie 1, Münster, Germany (Recruiting)
  • Diakoniekrankenhaus Rotenburg(Wümme)gGmbH, Zentrum für Pneumologie, Rotenburg, Germany (Withdrawn)

Study Officials